Skip to Content

Rule

FDA Regulations; Technical Amendment

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending a regulatory hearing process regulation to correct an inaccurate citation, and regulations pertaining to biological products to correct two typographical errors. FDA is also amending certain medical device regulations to include references to and mailing address information for the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Devices and Radiological Health (CDRH). This action is being taken to ensure the accuracy of FDA's regulations.

DATES:

This rule is effective August 25, 2008.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Denise Sánchez, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-6210.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Background

FDA is amending 21 CFR 16.1 to correct an inaccurate citation and is amending 21 CFR 610.51 and 21 CFR 640.53 to correct typographical errors.

FDA is also amending its medical device regulations in 21 CFR 812, 814, and 860 to include references to and mailing addresses for CBER and CDER, and 21 CFR 822.8 to correct an inadvertent omission of the mailing address for CDRH. Submissions regarding a medical device must be sent to the address of the appropriate center that has regulatory responsibility for the medical device. Therefore, FDA is updating these regulations to include address information for all appropriate centers.

Publication of this document constitutes final action under the Administrative Procedures Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment to the regulations provides only technical changes to correct an inaccurate citation and typographical errors, and to update mailing addresses and other information, and is nonsubstantive.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act, and Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs,

End Amendment Part Start Part

PART 16—REGULATORY HEARING BEFORE THE FOOD AND DRUG ADMINISTRATION

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Start Printed Page 49942 Authority: 15 U.S.C. 1451-1461; 21 U.S.C. 141-149, 321-394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 U.S.C. 201-262, 263b, 364.

End Authority
[Amended]
Start Amendment Part

2. Section 16.1 is amended in paragraph (b)(2), by removing “§ 1270.15(e)” and adding in its place “§ 1270.43(e)”.

End Amendment Part Start Part

PART 610—GENERAL BIOLOGICAL PRODUCTS STANDARDS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360c, 360d, 360h, 360i, 371, 372, 374, 381; 42 U.S.C. 216, 262, 263, 263a, 264.

End Authority
[Amended]
Start Amendment Part

4. Section 610.53 is amended in paragraph (c) in the table, under column A, by removing the words “Cryoprecipitated AFH” and adding in their place “Cryoprecipitated AHF.”

End Amendment Part Start Part

PART 640—ADDITIONAL STANDARDS FOR HUMAN BLOOD AND BLOOD PRODUCTS

End Part Start Amendment Part

5. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371; 42 U.S.C. 216, 262, 263, 263a, 264.

End Authority
[Amended]
Start Amendment Part

6. Section 640.51 is amended in paragraph (b) by removing the word “Plasmaphersis” and adding in its place “Plasmapheresis.”

End Amendment Part Start Part

PART 812—INVESTIGATIONAL DEVICE EXEMPTIONS

End Part Start Amendment Part

7. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 331, 351, 352, 353, 355, 360, 360c-360f, 360h-360j, 371, 372, 374, 379e, 381, 382, 383; 42 U.S.C. 216, 241, 262, 263b-263n.

End Authority Start Amendment Part

8. Section 812.20 is amended by revising paragraph (d) to read as follows:

End Amendment Part
Application.
* * * * *

(d) Information previously submitted. Information previously submitted to the Center for Devices and Radiological Health, the Center for Biologics Evaluation and Research, or the Center for Drug Evaluation and Research, as applicable, in accordance with this chapter ordinarily need not be resubmitted, but may be incorporated by reference.

Start Part

PART 814—PREMARKET APPROVAL OF MEDICAL DEVICES

End Part Start Amendment Part

9. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 351, 352, 353, 360, 360c-360j, 371, 372, 373, 374, 375, 379, 379e, 381.

End Authority Start Amendment Part

10. Section 814.42 is amended by revising the fourth sentence of paragraph (d)(2) to read as follows:

End Amendment Part
Filing a PMA.
* * * * *

(d) * * *

(2) * * * If FDA does not reverse its decision not to file the PMA, the applicant may request reconsideration of the decision from the Director of the Center for Devices and Radiological Health, the Director of the Center for Biologics Evaluation and Research, or the Director of the Center for Drug Evaluation and Research, as applicable. * * *

* * * * *
Start Amendment Part

11. Section 814.100 is amended by revising paragraph (c)(2) to read as follows:

End Amendment Part
Purpose and scope.
* * * * *

(c) * * *

(2) Submitting an HDE to the Office of Device Evaluation (ODE), Center for Devices and Radiological Health (CDRH), the Center for Biologics Evaluation and Research (CBER), or the Center for Drug Evaluation and Research (CDER), as applicable.

* * * * *
Start Amendment Part

12. Section 814.104 is amended by revising paragraph (d) to read as follows:

End Amendment Part
Original applications.
* * * * *

(d) Address for submissions and correspondence. Copies of all original HDEs amendments and supplements, as well as any correspondence relating to an HDE, must be sent or delivered to the following:

(1) For devices regulated by the Center for Devices and Radiological Health, send this information to the Document Mail Center (HFZ-401), Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850.

(2) For devices regulated by the Center for Biologics Evaluation and Research, send this information to the Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448.

(3) For devices regulated by the Center for Drug Evaluation and Research, send this information to the Central Document Control Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

Start Part

PART 822—POSTMARKET SURVEILLANCE

End Part Start Amendment Part

13. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 331, 352, 360i, 360l, 371, 374.

End Authority Start Amendment Part

14. Section 822.8 is amended by adding a sentence after the first sentence to read as follows:

End Amendment Part
When, where, and how must I submit my postmarket surveillance plan?

* * * For devices regulated by the Center for Devices and Radiological Health, send three copies of your submission to the Postmarket Surveillance Document Center (HFZ-541), Epidemiology Branch, Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850-3229. * * *

Start Part

PART 860—MEDICAL DEVICE CLASSIFICATION PROCEDURES

End Part Start Amendment Part

15. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360c, 360d, 360e, 360i, 360j, 371, 374.

End Authority Start Amendment Part

16. Section 860.7 is amended by revising paragraph (g)(4) to read as follows:

End Amendment Part
Determination of safety and effectiveness.
* * * * *

(g) * * *

(4) Required information that has been submitted previously to the Center for Devices and Radiological Health, the Center for Biologics Evaluation and Research, or the Center for Drug Evaluation and Research, as applicable, need not be resubmitted, but may be incorporated by reference.

Start Amendment Part

17. Section 860.123 is amended by revising paragraph (b)(1) to read as follows:

End Amendment Part
Reclassification petition: Content and form.
* * * * *

(b) * * *

(1) For devices regulated by the Center for Devices and Radiological Health, addressed to the Food and Drug Administration, Center for Devices and Radiological Health, Regulations Staff Start Printed Page 49943(HFZ-215), 1350 Piccard Dr., Rockville, MD 20857; for devices regulated by the Center for Biologics Evaluation and Research, addressed to the Document Control Center (HFM-99), Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448; for devices regulated by the Center for Drug Evaluation and Research, addressed to the Central Document Control Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266, as applicable.

* * * * *
Start Signature

Dated: August 18, 2008.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

End Signature End Supplemental Information

[FR Doc. E8-19654 Filed 8-22-08; 8:45 am]

BILLING CODE 4160-01-S